

State of Oklahoma SoonerCare



Aimovig[®] (erenumab-aooe) Prior Authorization Form

Member Name:	Date of Birth:	Member II	D#:
Drug Information			
Pharmacy billing (NDC:) Start Date (or date of next dose):		
Dose: Regimen:		Fill Quantity:	Day Supply:
Pharmacy Information			
Pharmacy NPI:	Pharmacy Name:		
Pharmacy Phone:	Pharmacy Fax:		
Prescriber Information			
Prescriber NPI:	Prescriber Name:		
Prescriber Phone:	Prescriber Fax:	Specialty	/:
Criteria			
1. What is the member's diagnosis? Preventive treatment of migrature. Other, please list: Does the member have documented: Chronic Migraine Headache Episodic Migraine Headache Bepisodic Migraine diagnosis Number of member's migraine diagnosis Number of headache days per month Number of migraine days per month Has the member been evaluated for a conditions have been ruled out and/o a. Red flags? Yes No b. Possible indicators of seconds. C. Medication overuse? Yes Will member use Aimovig® concurrent calcitonin gene-related peptide (CGR) Has the member been counseled on Yes No No No No No No No No No N	ines in adults ? ? (if episodic migraine, numberall of the following, as definer treated: ary headache? Yes No No tly with botulinum toxin for P) inhibitor? Yes No	er of days on average for ed by the American Head	ne or with an alternative
 For Continued Authorization: Has the member been compliant with Has the member responded well to tree. Please provide the member's current Additional Information:	eatment with Aimovig [®] (ere number of migraine days p	enumab-aooe)? Yes per month:	
Additional Information:			
Prescriber Signature:	ally management of the first	Date:	the heat of mer line . It is
I certify that the indicated treatment is medic Please do not send in chart notes. Specific infor- processing delays.			

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts. All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available

at AetnaBetterHealth.com/Oklahoma.

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm – 104 4/8/2025